[go: up one dir, main page]

DK3368683T3 - Fremgangsmåde til kvantifikationen af pd-l1 - Google Patents

Fremgangsmåde til kvantifikationen af pd-l1 Download PDF

Info

Publication number
DK3368683T3
DK3368683T3 DK15795217.7T DK15795217T DK3368683T3 DK 3368683 T3 DK3368683 T3 DK 3368683T3 DK 15795217 T DK15795217 T DK 15795217T DK 3368683 T3 DK3368683 T3 DK 3368683T3
Authority
DK
Denmark
Prior art keywords
quantification
procedure
Prior art date
Application number
DK15795217.7T
Other languages
English (en)
Inventor
Evrykleia Lianidou
Areti Strati
Original Assignee
Pharmassist Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmassist Ltd filed Critical Pharmassist Ltd
Application granted granted Critical
Publication of DK3368683T3 publication Critical patent/DK3368683T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6853Nucleic acid amplification reactions using modified primers or templates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Liquid Crystal Substances (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
DK15795217.7T 2015-10-27 2015-10-27 Fremgangsmåde til kvantifikationen af pd-l1 DK3368683T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GR2015/000054 WO2017072539A1 (en) 2015-10-27 2015-10-27 Method for the quantification of pd-l1 expression

Publications (1)

Publication Number Publication Date
DK3368683T3 true DK3368683T3 (da) 2020-03-30

Family

ID=54548209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15795217.7T DK3368683T3 (da) 2015-10-27 2015-10-27 Fremgangsmåde til kvantifikationen af pd-l1

Country Status (14)

Country Link
US (2) US20190085401A1 (da)
EP (1) EP3368683B1 (da)
CY (1) CY1122871T1 (da)
DK (1) DK3368683T3 (da)
ES (1) ES2779309T3 (da)
HR (1) HRP20200487T1 (da)
HU (1) HUE048265T2 (da)
LT (1) LT3368683T (da)
PL (1) PL3368683T3 (da)
PT (1) PT3368683T (da)
RS (1) RS60075B1 (da)
SI (1) SI3368683T1 (da)
SM (1) SMT202000159T1 (da)
WO (1) WO2017072539A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12298309B2 (en) 2016-09-06 2025-05-13 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
US11726089B2 (en) 2016-09-06 2023-08-15 Incelldx, Inc. Methods of assaying neoplastic and neoplasia-related cells and uses thereof
CA3036278A1 (en) 2016-09-06 2018-03-15 Incelldx, Inc. Methods of detecting per cell pd-l1 expression and uses thereof
CN107460239A (zh) * 2017-07-23 2017-12-12 嘉兴允英医学检验有限公司 一种用于pd‑l1表达水平检测的试剂盒
EP3697927B1 (en) * 2017-10-19 2022-12-14 Bio-Rad Laboratories, Inc. Digital amplification assays with unconventional and/or inverse changes in photoluminescence
CN108507992A (zh) * 2018-04-09 2018-09-07 苏州大学附属第医院 循环肿瘤细胞表面标志分子pd-l1的检测方法
CA3109216A1 (en) * 2018-08-16 2020-02-20 Musc Foundation For Research Development Recombinant myxoma viruses and uses thereof
WO2020092589A1 (en) * 2018-10-31 2020-05-07 Nantomics, Llc Immune checkpoint therapeutic methods
CN109576350B (zh) * 2019-01-18 2021-01-29 深圳恒特基因有限公司 一种dna与rna同时定量的试剂盒、方法及质控方法
CN109628596A (zh) * 2019-01-18 2019-04-16 臻悦生物科技江苏有限公司 Rna水平检测pd-1和pd-l1表达量的试剂盒及方法
WO2020214606A1 (en) * 2019-04-15 2020-10-22 The Medical College Of Wisconsin, Inc. Recombinant pd-l1 peptides and methods of use
JP2022548752A (ja) * 2019-09-24 2022-11-21 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化細胞を含有体液サンプルのマルチモード解析
EP4060346A4 (en) * 2020-02-18 2023-12-13 Innobation Bio Co., Ltd. COMPANION DIAGNOSTIC BIOMARKER COMPOSITION AND COMPANION DIAGNOSTIC KIT CONTAINING SAME
CN111521796A (zh) * 2020-04-21 2020-08-11 山东第一医科大学(山东省医学科学院) 一种检测肾癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
US20230341407A1 (en) * 2020-08-19 2023-10-26 Ohio State Innovation Foundation Highly sensitive platform to characterize extracellular vesicular biomarkers for cancer immunotherapy
CN112462072B (zh) * 2020-09-24 2022-06-03 浙江大学 一种tmub1蛋白在制备肿瘤免疫抑制分子检测剂中的应用
CN112725418A (zh) * 2021-01-25 2021-04-30 深圳乐土生物科技有限公司 基于游离rna检测pd-l1表达量的方法及其试剂盒
CN115961033A (zh) * 2022-10-19 2023-04-14 深圳海普洛斯医学检验实验室 一种cd274基因检测的探针引物组合、试剂盒及检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797813B2 (en) * 1996-09-23 2004-09-28 Schering Corporation AK155 antibodies and binding fragments thereof
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
GB201021149D0 (en) 2010-12-14 2011-01-26 Georg August Uni Gottingen Stiftung Offentlichen Rechts Use of a skin explant assay for mRNA expression analysis for the identification of new genes and drug targets associated with graft versus host disease
US20150071910A1 (en) 2013-03-15 2015-03-12 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
ES2761260T3 (es) * 2013-03-15 2020-05-19 Hoffmann La Roche Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1
EP3189080A1 (en) * 2014-09-05 2017-07-12 Medimmune Limited Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)

Also Published As

Publication number Publication date
EP3368683A1 (en) 2018-09-05
LT3368683T (lt) 2020-04-10
ES2779309T3 (es) 2020-08-14
CY1122871T1 (el) 2021-05-05
SMT202000159T1 (it) 2020-05-08
PT3368683T (pt) 2020-04-06
HRP20200487T1 (hr) 2020-09-04
US20190085401A1 (en) 2019-03-21
HUE048265T2 (hu) 2020-08-28
WO2017072539A1 (en) 2017-05-04
SI3368683T1 (sl) 2020-07-31
US12270081B2 (en) 2025-04-08
EP3368683B1 (en) 2020-01-15
PL3368683T3 (pl) 2020-07-27
US20220073995A1 (en) 2022-03-10
RS60075B1 (sr) 2020-05-29

Similar Documents

Publication Publication Date Title
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3371171T3 (da) Inhibitorer af RET
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3241026T3 (da) Fremgangsmåde til absolut kvantificering af naturligt forarbejdede hla-begrænsede cancerpeptider
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3286311T3 (da) Fremgangsmåde til behandling af maligniteter
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3244891T3 (da) Forbindelser til forbedring af mrna-splejsning
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3344805T3 (da) Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
DK3397648T3 (da) Fremgangsmåde til deacetylering af biopolymerer
DK3371165T3 (da) Btk-inhibitor til anvendelse til behandling af kræft
DK3261726T3 (da) Sammensætning til behandling af acne
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3359522T3 (da) Proces til fremstilling af N-Boc-bifenylalaninol
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner